Theraclion specializes in developping, manufacturing and marketing echotherapy equipment associating therapy with focused ultrasound (HIFU) and monitoring by ultrasound. The company provides Echopulse, a device for non-invasive and outpatient treatment of mammary fibroadenoma and thyroid nodules.Net sales break down by activity as follows: - sale of consumables (52.8%); - sale of equipment (28.8%); - provision of after-sales services (18.4%). The vast majority of net sales are earned abroad.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

06-08	Theraclion Secures AMA CPT Editorial Panel Approval For New Category III CPT Code For Sonovein	CI
06-05	Theraclion deploys first Sonovein system in China

Market Cap	56.07M 65M 51.55M 48.52M 91.18M 6.13B 91.95M 611M 238M 3.01B 244M 239M 10.41B	P/E 2024	-2.66x	P/E 2025	-6.33x
Enterprise Value	63.93M 74.1M 58.77M 55.32M 104M 6.99B 105M 696M 271M 3.43B 278M 272M 11.87B	EV / Sales 2024	22.5x	EV / Sales 2025	55.4x
Free-Float	54.37%	Yield 2024 *	-	Yield 2025	-

06-08	Theraclion Secures AMA CPT Editorial Panel Approval For New Category III CPT Code For Sonovein	CI
06-05	Theraclion deploys first Sonovein system in China
06-05	Theraclion JV Deploys Sonovein System at Chinese Hospital	MT
06-04	Theraclion Deploys Sonovein System At Boao Super Hospital in Hainan Province	CI
06-01	Theraclion Presents Promising Preliminary Results From Sonovein SpeedPulse At First International HIFU Congress	CI
05-11	Bouygues, Euronext, Vallourec... stocks to watch today in Paris
05-11	Theraclion raises nearly 6 million euros via units with warrants
04-20	France's Theraclion Targets EUR6 Million via Capital Increase	MT
04-20	Casino, Rubis, Sanofi... stocks to watch today in Paris
04-20	Theraclion launches 12.48 million unit rights issue
04-16	Theraclion SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04-13	Weekly Earnings Calendar: JPMorgan and Netflix in the US, LVMH and ASML in Europe,
12-10	Theraclion Seeks US FDA Nod for Varicose Vein Treatment Platform	MT

06-08	Theraclion Secures Key U.S. Reimbursement Milestone for Sonovein® With AMA CPT Editorial Panel Approval of a New Category III CPT Code	BU
06-04	Theraclion Announces First Clinical Deployment of Sonovein® in Hainan, China	BU
06-01	Theraclion Announces the Success of the First International HIFU Congress in Parma, Where Promising Preliminary Results From Its Sonovein® SpeedPulse Were Presented	BU
05-11	Theraclion : Inside Information / Other news releases	PU
05-11	Theraclion Announces the Strong Success of Its Oversubscribed Capital Increase	BU

06-13	Agenda des dividendes et des AG France : GTT, Alten et Exail sur les tablettes
06-09	Bourse : GSK s'offre Nuvalent pour 10,6 MdsUSD, RIP le SCAF, Orange seul maître à bord en Espagne
06-09	La tech se remet la tête à l'endroit
06-08	THERACLION FRANCHIT UNE ÉTAPE CLÉ VERS LE REMBOURSEMENT AUX ÉTATS-UNIS AVEC L’APPROBATION D’UN CODE CPT DE CATÉGORIE III POUR SONOVEIN®
06-05	Bourse : Lululemon dévisse, Blackstone se protège, Schneider émet 850 MEUR d'OCEANE

Theraclion SA Stock Swiss Exchange

Stocks

FR0010120402

Advanced Medical Equipment & Technology

Valuation: Theraclion SA

Latest news : Theraclion SA

Press Releases: Theraclion SA

News in other languages: Theraclion SA

Managers and Directors: Theraclion SA

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Manager	Title	Age	Since
Martin Deterre CEO	Chief Executive Officer	-	2023-05-23
Julie Veisseire DFI	Director of Finance/CFO	-	-
Gaylord Tallec COO	Chief Operating Officer	-	-

Director	Title	Age	Since
Renaud Saleur BRD	Director/Board Member	-	2018-01-31
Ari Kellen BRD	Director/Board Member	-	2019-02-12
Shawn Langer BRD	Director/Board Member	-	2019-02-12

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THERMO FISHER SCIENTIFIC, INC.	-2.31%	-4.22%	+18.30%	-14.07%	172B
INTUITIVE SURGICAL, INC.	-3.57%	-2.39%	-21.47%	+22.11%	142B
DANAHER CORPORATION	-1.98%	-3.20%	-9.19%	-26.48%	126B
BOSTON SCIENTIFIC CORPORATION	-4.20%	-7.01%	-55.81%	-17.25%	66.81B
EDWARDS LIFESCIENCES CORPORATION	-2.14%	+0.81%	+18.30%	-5.72%	49.91B
SIEMENS HEALTHINEERS AG	-1.84%	-1.28%	-24.46%	-34.38%	44.81B
AGILENT TECHNOLOGIES, INC.	-3.12%	-5.54%	+7.10%	+2.64%	35.11B
WATERS CORPORATION	-0.98%	-1.70%	+4.66%	+32.62%	35.05B
GE HEALTHCARE TECHNOLOGIES INC.	-3.29%	-4.09%	-14.04%	-22.25%	27.82B
Average	-1.85%	-3.15%	-8.51%	-6.98%	77.7B
Weighted average by Cap.	-2.07%	-3.30%	-7.10%	-7.09%

	2024	2025
Net sales	830K 962K 763K 718K 1.35M 90.82M 1.36M 9.05M 3.52M 44.57M 3.61M 3.53M 154M	652K 756K 599K 564K 1.06M 71.32M 1.07M 7.1M 2.77M 35M 2.84M 2.78M 121M
Net income	-5.76M -6.67M -5.29M -4.98M -9.36M -630M -9.44M -62.73M -24.42M -309M -25.05M -24.51M -1.07B	-5.69M -6.6M -5.23M -4.92M -9.25M -622M -9.33M -61.99M -24.14M -305M -24.75M -24.23M -1.06B
Net Debt	3.41M 3.95M 3.14M 2.95M 5.55M 373M 5.59M 37.16M 14.47M 183M 14.84M 14.52M 633M	7.85M 9.1M 7.22M 6.79M 12.77M 859M 12.88M 85.55M 33.31M 422M 34.16M 33.43M 1.46B

End-of-day quote Swiss Exchange Other stock markets
- ^EUR	-